T-group (topology)
5000.3.1 Bcl-2 inhibitors of programmed cell death
Ligands and drugs
1,175
Member domains
640
with ligand contacts (≤ 4 Å)
54.5% of members
562
with DrugDomain annotations
47.8% of members
235
with a DrugBank compound
20.0% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 5000.3.1 belongs to X-group 5000 Toxins' membrane translocation domains, which binds 10.9 ligand superclasses per 20 proteins, broader than 98% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB12340 | 1XJ | Navitoclax | 16 |
| DB17023 | N3C | ABT-737 | 8 |
| DB04327 | PEE | Phosphatidylethanolamine | 6 |
| DB11581 | LBM | Venetoclax | 5 |
| DB18365 | F3Q | S-55746 | 3 |
| DB01694 | TAR | D-tartaric acid | 2 |
| DB02042 | 1PG | 2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol | 2 |
| DB02676 | B3P | 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol | 2 |
| DB01050 | — | — | 1 |
| DB01229 | — | Paclitaxel | 1 |
| DB01248 | — | Docetaxel | 1 |
| DB01367 | — | Rasagiline | 1 |
| DB02580 | PG6 | Pentaglyme | 1 |
| DB02774 | PDO | 1,3-Propanediol | 1 |
| DB02994 | CAD | Cacodylic acid | 1 |
| DB03309 | NHE | N-cyclohexyltaurine | 1 |
| DB03627 | ADM | Adamantane | 1 |
| DB05103 | — | — | 1 |
| DB05297 | — | — | 1 |
| DB06307 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 39 |
| CL | CHLORIDE ION | 33 |
| 1XJ | 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide | 15 |
| CUmetal | COPPER (II) ION | 13 |
| 19G | 3-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-benzothiophene-2-carboxylic acid | 12 |
| 4M6 | 1-[3-(naphthalen-1-yloxy)propyl]-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-2-carboxylic acid | 12 |
| 4M7 | (1R)-7-[3-(naphthalen-1-yloxy)propyl]-3,4-dihydro-2H-[1,4]thiazepino[2,3,4-hi]indole-6-carboxylic acid 1-oxide | 12 |
| 8SP | O-[(R)-{[(2R)-2,3-bis(octanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine | 12 |
| QHP | (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methylbenzyl)ureido)-3-(((3R,5R,7R)-adamantan-1-ylmethyl)sulfonyl)propanoic acid | 12 |
| QHS | (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methylbenzyl)ureido)-3-((cyclohexylmethyl)sulfonyl)propanoic acid | 12 |
| 6AK | 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid | 10 |
| NAmetal | SODIUM ION | 10 |
| 38H | 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl]-5-{3-[4-(1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenoxy]propyl}-1,3-thiazole-4-carboxylic acid | 8 |
| CDmetal | CADMIUM ION | 8 |
| LC6 | 7-(4-{[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-2-methylphenyl)-3-[3-(naphthalen-1-yloxy)propyl]pyrazolo[1,5-a]pyridine-2-carboxylic acid | 8 |
| N3C | 4-{4-[(4'-CHLOROBIPHENYL-2-YL)METHYL]PIPERAZIN-1-YL}-N-{[4-({(1R)-3-(DIMETHYLAMINO)-1-[(PHENYLTHIO)METHYL]PROPYL}AMINO)-3-NITROPHENYL]SULFONYL}BENZAMIDE | 8 |
| PG8 | 1,2-DIOCTANOYL-SN-GLYCERO-3-[PHOSPHO-RAC-(1-GLYCEROL) | 8 |
| 19H | 6-chloro-3-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1H-indole-2-carboxylic acid | 7 |
| BR | BROMIDE ION | 7 |
| 2UU | 4-(4-methylnaphthalen-1-yl)-2-{[(4-phenoxyphenyl)sulfonyl]amino}benzoic acid | 6 |